Paricalcitol Synthesis via Ozonolysis and Segmentation
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Current methods for synthesizing biologically active 19-nor-analogs of 1α-hydroxylated vitamin D compounds, such as Paricalcitol, are not efficient and lack a comprehensive process for producing these compounds with specific structural modifications that reduce calcemic activity while maintaining therapeutic efficacy.
Innovation Solution
A novel process involving a series of chemical reactions, including ozonolysis, hydride reduction, and sulfonyl chloride treatment, is developed to synthesize compounds with specific side chain modifications, such as reacting an intermediate compound with n-butyl lithium and a compound having a specific alkylsilyloxy group in dry THF, to produce Paricalcitol and its intermediates, allowing for controlled structural variations.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Productivity
If current synthesis methods are used for 19-nor-vitamin D compounds, then the structural modifications can be achieved, but the synthesis efficiency is low and the process is not comprehensive
Solution Approach 1:
The synthesis process is divided into distinct sequential steps: (1) formation of cyclovitamin D2 from vitamin D2, (2) ozonolysis of the side chain, (3) hydride reduction to form the alcohol, (4) tosylate formation, and (5) substitution with iodide. Each step is optimized independently to improve overall efficiency while maintaining manageable complexity at each stage.
Solution Approach 2:
The cyclovitamin D2 intermediate is prepared in advance and can be stored for subsequent use. The ozonolysis step is performed as a preliminary action to create the aldehyde functionality that enables the subsequent reduction and substitution reactions, streamlining the overall synthesis pathway.
2Reliability
If structural modifications are made to reduce calcemic activity, then therapeutic efficacy is maintained, but the manufacturing precision requirements increase
Solution Approach 1:
The synthesis selectively modifies specific regions of the vitamin D molecule: the side chain is ozonolysed to create the 22-iodo-23-hydroxy configuration, while the steroidal core structure is preserved through the cyclovitamin formation. This localized modification approach ensures the desired pharmacological properties are achieved without compromising the essential structural features for therapeutic activity.
Solution Approach 2:
The synthesis employs controlled parameter changes at each step: temperature control during ozonolysis and reduction, specific reagent ratios for tosylate formation, and controlled substitution conditions to introduce the iodide. These parameter optimizations ensure high stereochemical purity and structural precision in the final 19-nor-vitamin D2 product.
Applied Scientific Principles
This section explains which scientific principles are used to turn an abstract innovation direction into a practical engineering solution.
Function Achieved in This Case
This process enables the efficient production of Paricalcitol with tailored structural features, reducing calcemic activity while preserving the therapeutic benefits of vitamin D analogs, making them suitable for treating conditions like renal osteodystrophy and malignancies.
Implementation Method 1
The compound of formula 10 is treated with ozone to form the compound of formula 11
Implementation Method 2
The compound of formula 11 is treated with a hydride reducing agent, such as sodium borohydride, to form the compound of formula 12
Implementation Method 3
reacting an intermediate compound with n-butyl lithium and a compound having a specific alkylsilyloxy group in dry THF
Data Source
AI summary
The invention relates to a novel process for the preparation of Paricalcitol and intermediates thereof.